X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to advance a pipeline of orally delivered enzymes targeting malabsorption syndromes and nutrient metabolism disorders, including ANG003, a novel broad-spectrum orally delivered enzyme replacement therapy.
Lead Product(s): ANG003
Therapeutic Area: Genetic Disease Product Name: ANG003
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Anagram Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 04, 2023
Details:
The cmpanies have entered into a collaboration to leverage ATUM’s Leap-In Transposase® platform to develop the cell line essential to the manufacturing of Phylex’s universal SARS coronavirus vaccine candidate.
Lead Product(s): VLP based coronavirus vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Phylex BioSciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
